MethylGene's MGCD0103 enters phase 2 lymphoma trial

By Elaine Rigoli

Tampa, Fla., Aug. 22 - MethylGene, Inc. has enrolled its first patient in a single-agent phase 2 clinical trial of its lead HDAC compound, MGCD0103, in patients with relapsed or refractory Hodgkin's lymphoma.

The start of the study results in milestone payments from the company's partners, Pharmion Corp. and Taiho Pharmaceutical, of $4 million and $1.5 million, respectively.

In this open-label trial, MGCD0103 will be given orally at a dose of 110 mg, three times per week to patients with Hodgkin's lymphoma who have failed other treatments or whose disease has relapsed, according to a news release.

MethylGene is a biopharmaceutical company located in Montreal.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.